Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
AstraZeneca
US Department of Justice
Cantor Fitzgerald
Julphar
Daiichi Sankyo
Queensland Health
Federal Trade Commission
Accenture

Generated: January 22, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Elotuzumab

« Back to Dashboard

US Patents for Elotuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Elotuzumab ➤ Sign Up Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) ➤ Sign Up
Elotuzumab ➤ Sign Up Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ) ➤ Sign Up
Elotuzumab ➤ Sign Up Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) ➤ Sign Up
Elotuzumab ➤ Sign Up Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA) ➤ Sign Up
Elotuzumab ➤ Sign Up Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ➤ Sign Up
Elotuzumab ➤ Sign Up Therapeutic agents Purdue Pharmaceutical Products L.P. (Stamford, CT) ➤ Sign Up
Elotuzumab ➤ Sign Up P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) ➤ Sign Up
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Elotuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Elotuzumab Australia 2015341301 2034-10-30 ➤ Sign Up
Elotuzumab Canada 2966038 2034-10-30 ➤ Sign Up
Elotuzumab China 105566290 2034-10-30 ➤ Sign Up
Elotuzumab European Patent Office 3214081 2034-10-30 ➤ Sign Up
Elotuzumab Japan 2017533955 2034-10-30 ➤ Sign Up
Elotuzumab South Korea 20170078740 2034-10-30 ➤ Sign Up
Elotuzumab World Intellectual Property Organization (WIPO) 2016065980 2034-10-30 ➤ Sign Up
Drugname Country Document Number Estimated Expiration Related US Patent

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
Citi
Boehringer Ingelheim
Argus Health
Moodys
Medtronic
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.